Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02854839
Other study ID # MG4101-HCC-P2a
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 28, 2016
Est. completion date September 17, 2019

Study information

Verified date October 2018
Source Green Cross LabCell Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).


Description:

This is randomized, multi-center, open-labeled, Phase 2a study in patients with HCC after transarterial chemoembolization (TACE). A total of 78 patients will be randomized(1:1) into one of the two group, to receive adjuvant therapy using MG4101 (allogeneic Natural killer cells, Treatment group) or no adjuvant therapy (Control group).

Patients who were assigned Treatment group will receive 2 cycles of MG4101 (each cycle is 3 treatments at a frequency of once per week, between each cycle has 3 weeks of withdrawal period). After treatment period, patients will undergo follow up for progression and survival every 12 weeks (± 7 days) and follow up 1 year after the last patient`s enrollment date.

The Control group`s patients will will undergo follow up for progression and survival every 12 weeks (± 7 days) and follow up 1 year after the last patient`s enrollment date.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date September 17, 2019
Est. primary completion date September 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria

1. Patients who are between 20 to 80 years of age

2. Life expectancy > 12 weeks

3. Patients have complete remission according to the mRECIST by Dynamic contrast-enhanced 3- or 4-phase CT or tissue biopsy

- Patients were diagnosed Hepatocellular Carcinoma BCLC stage B be-fore TACE.

- Dynamic contrast-enhanced CT must be within 4 weeks after the TACE.

4. Previous TACE with the following:

- Lipiodol mixed with chemotherapy (such as adriamycin etc.)

- Used with Gelatin sponge or Polyvinyl alcohol or microsphere.

5. Patients who had local treatment such as Resection, Radiofrequency Ablation, Percutaneous ethanol injection and Transarterial chemoembolization can participates study.

6. Patients whose Child-Pugh score is less than B8.

7. Patients whose ECOG score is 0

8. Patients who satisfy the following conditions of the blood test, kidney function test, and liver function test.

- Absolute neutrophil count = 1,000 x 10^6 /L

- hemoglobin level = 8.5 g/?

- platelet count = 50,000 /?

- Total bilirubin < 3.0 ?/?

- Serum creatinine = 1.5 x upper normal limit (UNL)

- Total Albumin = 2.8 ?/?

9. Able and willing to provide written informed consent and to comply with the study protocol.

Exclusion criteria

1. Patients who have metastasis.

2. Patients who have Portal vein or hepatic vein invasion.

3. Patient with medical history for the following:

- Patients with Living donor Liver Transplantation or Orthotopic liver transplantation.

- Patients who have received anti-cancer chemotherapy for 4 weeks prior to the study.

- Patients who have not recovered adverse reaction prior to the study.

- Patients who have received external beam radiation on liver, immunotherapy, cell therapy, and target therapy.

- Prior use of systemic anticancer chemotherapy twice.

4. Patients who have a history of malignant tumors in 5 years prior to the study with the exception of Carcinoma in situ..

5. Patients who have a history of autoimmune disease such as Rheuma-toid arthritis, systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis, Adolescent Insulin-dependent Diabetes Mellitus, etc.

6. Patients who have history of human immunodeficiency virus (HIV) infection.

7. Patients who have participated in other clinical trials within 4 weeks prior to this study.

8. Patients who treated with immunosuppressant for 3 months prior to this study.

9. Patients who have any condition that was uncontrolled or needed treatment.

10. Pregnant or breast-feeding subjects.

Study Design


Intervention

Biological:
MG4101
MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.

Locations

Country Name City State
Korea, Republic of Korea Univ. Guro Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul Asan Medical center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance hospital Seoul
Korea, Republic of Ajou Univ. Hospital Suwon

Sponsors (1)

Lead Sponsor Collaborator
Green Cross LabCell Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time To progression every 12 weeks, up to the time of death or 18 months
Secondary Progression-free survival every 12 weeks, up to the time of death or tumor progression, up to 18 months
Secondary Overall survival every 12 weeks, up to the time of death, up to 18 months
Secondary change of Tumor Markers(AFP, Alpha-Fetoprotein) every 12 weeks, up to the time of death or tumor progression, up to 18 months
Secondary Safety of MG4101 as evaluated by Incidence of adverse events (AEs), serious adverse events (SAEs) up tp 9 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2